Several studies have reported positive correlations between mucosal Fusobacterium nucleatum burden and clinical indicators of active disease, endoscopic severity scores, fecal calprotectin concentrations, and serum C-reactive protein (CRP) levels, supporting its role as a potential biomarker of IBD activity (Table 2). This evidence concerns the gene CRP and inflammatory bowel disease.